Range of eligible patients: CDEC talked over the uncertainty in the volume of people with reasonably critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some sufferers who're categorised as acquiring delicate or moderate disease can have a critical bleeding pheno